Novo Nordisk's pricing methods inside the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who has accused the company of price gouging, declaring the stark contrast among U.S. price ranges and people in Europe and copyright. The maker claims that good use of copyright